| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/02/2008 | US20080241219 Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; macular degeneration |
| 10/02/2008 | US20080241217 Compositions and methods for coating medical implants |
| 10/02/2008 | US20080241215 Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke |
| 10/02/2008 | US20080241212 Tyrosine-derived aromatic polyester sheet, film or mat of nanofibers optionally including anesthetics, antiinflammatories, microbiocides, leukotriene inhibitors, or antiscarring, antifibrotic, or antineoplastic agents, and that resists capsular contracture and adherence to the implant |
| 10/02/2008 | US20080241211 Carrier matrix having an osteoinductive agent selected from TGF- beta or a bone morphogenic protein, and an osteoinductive enhancer, preferably naringin, integrated therein; dentistry |
| 10/02/2008 | US20080241207 Culture medium; antibodies; bioassays; drug screening; administering with an agonist or antagonist; stromal cells; implants |
| 10/02/2008 | US20080241203 A biodegradable woven cloth, a nonwoven fabric, a sheet, or sponge having a surgical adhesion prevention layer; wound healing agents |
| 10/02/2008 | US20080241199 "Micro-Patch" for Assessment of the Local Microvasculature and Microcirculatory Vasoreactivity |
| 10/02/2008 | US20080241198 Selective angiogenesis and gene expression inhibition of the vascular endothelial growth factor pathway; ocular disease; antiarthritic, antiinflammatory agents |
| 10/02/2008 | US20080241197 Minocycline dosage forms for the treatment of acne |
| 10/02/2008 | US20080241196 Invasin complex comprising lipopolysaccharide component from gramnegative bacteria for use as tool to facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes |
| 10/02/2008 | US20080241194 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage |
| 10/02/2008 | US20080241186 Nucleic acid vaccines for prevention of flavivirus infection |
| 10/02/2008 | US20080241179 Structural proteins of fish pancreatic disease virus and uses thereof |
| 10/02/2008 | US20080241173 Using FLT3 kinase as tool in identifying modulators for treatment and prevention of hematopoietic stem cell disease |
| 10/02/2008 | US20080241167 Inhibiting membrane fusion between human immunodeficiency virus and chemokine receptor-5 expressing cells using receptor specific immunoglobulins |
| 10/02/2008 | US20080241165 Controlling extracellular protein degradation and/or clearance via modulation of tissue plasminogen activator activity; treating diabetic, autoimmune, cardiovascular, blood and nervous system disorders |
| 10/02/2008 | US20080241157 Nerve cell growth modulators (amphibodies) |
| 10/02/2008 | US20080241151 Neisserial peptides for use in developing vaccine for prevention and treatment of menigococcal septicemia and meningitis |
| 10/02/2008 | US20080241150 Peptide comprising Lin12-Notch repeats (LNR) for use in identifying and designing modulators for prevention and treatment of cell proliferative disorders |
| 10/02/2008 | US20080241148 Treatment with anti-vegf antibodies |
| 10/02/2008 | US20080241147 Using pleckstrin homology (PH) domain-interacting protein as tool in detection and identification of modulators for prevention and treatment of cell proliferative disorders |
| 10/02/2008 | US20080241144 Prohibitin as Target for Cancer Therapy |
| 10/02/2008 | US20080241140 Gene amplification of coactivator coaa and uses thereof |
| 10/02/2008 | US20080241133 Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor |
| 10/02/2008 | US20080241132 Using serine/threonine kinase inhibitors to treat cell proliferative disorders |
| 10/02/2008 | US20080241131 Using sphingosine kinase-2 as tool in identifying modulators for use in treatment of cell proliferative disorders |
| 10/02/2008 | US20080241129 Adipocyte secreted protein ccdc80 is a potent stimulator of bone formation |
| 10/02/2008 | US20080241120 Therapeutic mixturecomprising pilocarpine combined with bioadhesive polymer for use in treatment of reduced salivation |
| 10/02/2008 | US20080241119 Nutrient mix for use treatment of respiratory and cardiovascular disodrers |
| 10/02/2008 | US20080241117 Alpha, beta, gamma and delta tocopherol enhanced mix for treatment of gingivitis; toohpaste |
| 10/02/2008 | US20080241110 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
| 10/02/2008 | US20080241105 Pretreatment with oncolytic virus |
| 10/02/2008 | US20080241102 Nucleophile/biodrug cascades |
| 10/02/2008 | US20080241101 Nutrient broth comprising serine protease inhibitors and cytokine for use propgation of skin basement membrane tissues; regenerative medicine; tissue repair |
| 10/02/2008 | US20080241097 Methods of treating neurological conditions with hematopoeitic growth factors |
| 10/02/2008 | US20080241095 Adding antifouling agents based on a polyolefin of one or more C2-C10 monomers having a C4-C10 monounsaturated dicarboxylic acid end group; polyisobutylene succinic anhydride; low dosage; used especially for ethylene dichloride distillation units, polychloroprene containing ferric ions; solvent mixtures |
| 10/02/2008 | US20080241094 An oral dosage form containing a polymer that swells upon absorbing water from gastric fluid to increase its size thereby promoting its gastric retention, maintains its physical integrity in a stomach for at least 2 hours, and is degradable by an intestinal enzyme or exposure to an intestinal pH |
| 10/02/2008 | US20080241093 A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic |
| 10/02/2008 | US20080241092 Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic |
| 10/02/2008 | US20080241085 Topically applying to skin a composition comprising a glycerophospholipid having a single fatty acid moiety, such as lysophosphatidylcholine; induce tyrosinase activity and melanocyte-stimulating hormone; sunless tanning; nontoxic; protective coatings; photoprotection |
| 10/02/2008 | US20080241081 Amide compound or salt thereof, and biofilm remover containing the same |
| 10/02/2008 | US20080241080 Composition for treating xerostomia or dry mouth |
| 10/02/2008 | US20080241078 Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins |
| 10/02/2008 | US20080241077 Benzoylguanidine salt and hydrates thereof |
| 10/02/2008 | US20080241076 Administering orally a composition comprised of the omega 6 fatty acid, arachidonic acid, to increase red blood cells leading to an increase in tissue oxygenation and thus athletic endurance; includes nutrients vitamins, minerals, along with phosphate, herbs and natta kinase, a proteolytic enzyme |
| 10/02/2008 | US20080241074 Multi-use multimodal imaging chelates |
| 10/02/2008 | US20080241070 Fenofibrate dosage forms |
| 10/02/2008 | US20080241067 co-culturing cancer cells and host cells for a time sufficient to detect evidence of gene expression in co-culture for simulating the progression from a primary tumor to a metastasis in an in vitro model; anti-EphA2 ( epithelial cell kinase) antibody |
| 10/02/2008 | US20080241064 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/02/2008 | DE102007015824A1 Agent, useful for the treatment of udder mastitis in mammals, preferably dairy cattle and of breast mastitis in humans, comprises an aqueous solution of N-chlorotaurine or its salt, preferably sodium salts |
| 10/02/2008 | DE102007015169A1 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| 10/02/2008 | DE102007015035A1 Substituierte Dibenzoesäure-Derivate und ihre Verwendung Substituted dibenzoic acid derivatives and their use |
| 10/02/2008 | DE102007015034A1 Lactam-substituierte Dicarbonsäuren und ihre Verwendung Lactam substituted dicarboxylic acids and their use |
| 10/02/2008 | DE102007014375A1 Oleylphosphocholin Oleylphosphocholine |
| 10/02/2008 | CA2685202A1 Methods for treating allergic asthma |
| 10/02/2008 | CA2682490A1 Prompt nucleic acid delivery carrier composition |
| 10/02/2008 | CA2682258A1 Methods and compositions of derivatives of probucol for the treatment of diabetes |
| 10/02/2008 | CA2682179A1 Allyl sulfide compounds, and compositions and methods using said compounds for repelling blood-feeding arthropods |
| 10/02/2008 | CA2682163A1 Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
| 10/02/2008 | CA2682050A1 Pharmaceutical composition comprising a cytokine |
| 10/02/2008 | CA2682049A1 Oral contraceptive regimen |
| 10/02/2008 | CA2682039A1 Cosmetic preparations designed to reduce unsightly cellulite |
| 10/02/2008 | CA2682019A1 Purinyl derivatives and their use as potassium channel modulators |
| 10/02/2008 | CA2682016A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| 10/02/2008 | CA2682015A1 Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
| 10/02/2008 | CA2682012A1 Substituted pyrrolidinamides, manufacturing and use thereof as medicaments |
| 10/02/2008 | CA2681934A1 11beta-hsd1 active compounds |
| 10/02/2008 | CA2681821A1 Indole carboxamides as ikk2 inhibitors |
| 10/02/2008 | CA2681771A1 Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity |
| 10/02/2008 | CA2681740A1 Improved preparation of oxymorphone from oripavine |
| 10/02/2008 | CA2681739A1 Novel imidazo based heterocycles |
| 10/02/2008 | CA2681728A1 Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease |
| 10/02/2008 | CA2681718A1 Hiv-1 protease inhibitors |
| 10/02/2008 | CA2681695A1 2-aminopyridine analogs as glucokinase activators |
| 10/02/2008 | CA2681650A1 The use of pde7 inhibitors for the treatment of movement disorders |
| 10/02/2008 | CA2681597A1 Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist |
| 10/02/2008 | CA2681591A1 Pulverized crystals of olmesartan medoxomil |
| 10/02/2008 | CA2681572A1 Inhibitors of ion channels |
| 10/02/2008 | CA2681545A1 Fluorinated derivatives of deferiprone |
| 10/02/2008 | CA2681536A1 Pyrimido[4,5-d]azepine derivatives as 5-ht2c agonists |
| 10/02/2008 | CA2681393A1 New imidazolo-heteroaryl derivatives and biological applications thereof |
| 10/02/2008 | CA2681379A1 Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection |
| 10/02/2008 | CA2681206A1 8-(heteroarylmethoxy)quinoline compounds as bradykinin b2 receptor modulators |
| 10/02/2008 | CA2681146A1 Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists |
| 10/02/2008 | CA2681134A1 Mineralocorticoid receptor modulators |
| 10/02/2008 | CA2681034A1 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 10/02/2008 | CA2681030A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 10/02/2008 | CA2680920A1 Treatment of female sexual dysfunction by compounds that positively modulate ampa-type glutamate receptors |
| 10/02/2008 | CA2680775A1 Aza-pyridopyrimidinone derivatives |
| 10/02/2008 | CA2680517A1 Novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure |
| 10/02/2008 | CA2680106A1 Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same |
| 10/02/2008 | CA2680046A1 Methods of diagnosing, classifying and treating endometrial cancer and precancer |
| 10/02/2008 | CA2680018A1 Combination medicaments for treating bacterial infections |
| 10/02/2008 | CA2679885A1 Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs) |
| 10/02/2008 | CA2679391A1 Method for treating and preventing arthritis |
| 10/02/2008 | CA2679267A1 Compound |
| 10/02/2008 | CA2679067A1 Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders |
| 10/02/2008 | CA2678272A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 10/02/2008 | CA2677991A1 Thiazolidine derivatives |